SIGN UP

Tom Miller, Iambic Therapeutics CEO

May 5, 2025 08:30 AM EDTUpdated 09:24 AM

Iambic debuts next version of AI model Enchant, driving new way for drug R&D

Andrew Dunn

Senior Biopharma Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Recursion cuts nearly half of its pipeline, including its most advanced program

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

Unity lays off 'all' workers; Novo to get FDA decision on oral Wegovy this year

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges